• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

    6/3/25 7:15:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Unlocking a New Dimension of Personalized Digital Healthcare for Millions Across Europe

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims & Hers will establish its own branded presence, leveraging the robust ZAVA platform, in each of these European markets in the coming quarters.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603806947/en/

    This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.

    This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.

    By combining ZAVA's trusted European operations, medical rigor, and seamless digital experience with Hims & Hers' proven, trusted brand, the company is poised to become a leader in digital health globally, delivering access to personalized care that meets people where they are. This strategic acquisition will significantly strengthen Hims & Hers' international footprint. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France, and Ireland.

    Hims & Hers will soon introduce a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. While Hims & Hers will share more about the offerings and their rollout in the coming months, they expect the deal to be accretive by 2026.

    "The demand for simpler, more personalized healthcare is universal," said Andrew Dudum, founder and CEO of Hims & Hers. "By leveraging ZAVA's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve."

    "Wherever you live, the need is the same: healthcare that's personal, trustworthy and fast. By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe," said David Meinertz, co-founder and CEO of ZAVA. "Together we'll pair ZAVA's trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I'm thrilled to be working with Andrew and his team. It's still day one for digital healthcare, and I can't wait to see what we'll achieve for patients in the years ahead."

    The acquisition consideration will be comprised of 100% cash, to be funded from the company's balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow.

    For more information, please see news.hims.com.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    About ZAVA

    ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated "outstanding" for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, certain statements in this press release, including statements regarding the timing and effects of entering into the acquisition described above, our future performance, anticipated customer demand, the ability to scale our business, the solutions accessible on our platform, and the underlying assumptions with respect to the foregoing, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission"). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250603806947/en/

    Press Contact

    Susan Cadrecha

    [email protected]

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    More analyst ratings

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    KeyBanc Capital Markets initiated coverage on Hims & Hers Health

    KeyBanc Capital Markets initiated coverage of Hims & Hers Health with a rating of Sector Weight

    10/21/25 7:20:02 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

    San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you. Purpose and Scope This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss

    2/5/26 8:51:30 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form 10-K filed by Hims & Hers Health Inc.

    10-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/23/26 5:20:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/23/26 4:07:25 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/19/26 6:19:32 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 5,262 shares at a strike of $5.01 and sold $139,108 worth of shares (5,262 units at $26.44) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    2/4/26 4:13:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 9,067 shares at a strike of $6.27 and sold $275,114 worth of shares (9,067 units at $30.34) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/21/26 4:23:35 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 5,986 shares at a strike of $9.16 and sold $306,453 worth of shares (9,070 units at $33.79), decreasing direct ownership by 3% to 91,617 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/7/26 4:16:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care